|Day's Range||6.95 - 7.83|
|52 Week Range||3.11 - 9.93|
|PE Ratio (TTM)||-2.84|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The company announced a stock offering that will bolster its balance sheet but also dilute current investors.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares are jumping up close to 16% after the drug maker released top-line data from its Phase 3 study of IV eravacycline in complicated Intra-Abdominal Infections. Though Needham analyst Alan Carr appreciates that Tetraphrase hit both the FDA's as well as the EMA's primary endpoints, he surveys the stock's potential from the sidelines, apprehensive on how much of a commercial success can await an "IV-only drug-" even anticipating approval.
The company announced positive top-line results from a phase 3 trial, which means regulatory submissions are on the way.